drugset / Trial / NCT02666742
DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation
Phase 4
Completed
246 enrolled
Kansas City Heart Rhythm Institute
Kansas City Heart Rhythm Research Foundation · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this study is to learn if taking a drug called direct oral anticoagulant after an ablation procedure keeps blood clots from forming and lowers the chance of having a stroke in patients with ventricular tachycardia or arrhythmia (VT).
Timeline
- Start
- 2017-02-16
- Primary completion
- 2020-05-01
- Completion
- 2021-04-30
Outcome
Met primary endpoint
registry NUMBER DOAC: 6 participants NCT02666742 ↗
registry analysis (superiority test); DOAC vs Aspirin; p = 0.001; Chi-squared NCT02666742 ↗
Publications
- Background Cabral KP, Ansell JE. The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag. 2015 Jan 30;11:117-23. doi: 10.2147/VHRM.S39726. eCollection 2015.
- Background Ghanbari H, Baser K, Jongnarangsin K, Chugh A, Nallamothu BK, Gillespie BW, Baser HD, Suwanagool A, Crawford T, Latchamsetty R, Good E, Pelosi F Jr, Bogun F, Morady F, Oral H. Mortality and cerebrovascular events after radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2014 Sep;11(9):1503-11. doi: 10.1016/j.hrthm.2014.05.003. Epub 2014 May 6.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixiban | Unknown | — | — |
| Comparator | Aspirin | Small molecule | 81 mg | Oral |
| Subject | Dabigatran | Unknown | — | — |
| Subject | Edoxaban | Small molecule | — | — |
| Subject | Rivaroxaban | Other / unclassified | — | — |